- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has seen its market value decline despite a strong biotech sector.
- An analyst from Jefferies set a price target of $230.00 for Alnylam Pharmaceuticals after the company lowered its 2026 sales guidance by approximately $200 million.
- A significant share drop of $81.14 has prompted a legal investigation into potential securities law violations.
Alnylam Pharmaceuticals, Inc. is a biotechnology company that develops novel medicines. While the broader biotech sector is performing well, Alnylam Pharmaceuticals has seen its market value fall. For example, the iShares Biotechnology ETF (NASDAQ:IBB) recently hit new all-time highs, but Alnylam Pharmaceuticals is one of only two stocks in the red among the top 20 companies in that index, as highlighted by Bespoke Investment Group.
On August 28, 2026, an analyst from Jefferies set a price target of $230.00 for Alnylam Pharmaceuticals. A price target is an analyst’s projection of a stock’s future price. At the time, the stock was trading at $233.50 per share, meaning the analyst expected a slight decrease in its value from that point.
This analyst view follows the company’s announcement on July 30, 2026, where it lowered its full-year 2026 sales guidance. Management reduced the total projected net product revenues for its TTR products by approximately $200 million. The company explained this was due to a slowdown after an initial surge in demand.
Following this news, Alnylam Pharmaceuticals’ shares fell sharply by $81.14 per share, as detailed by GlobeNewswire. This significant drop has also led to an investigation by law firm Kirby McInerney LLP. The firm is looking into potential violations of federal securities laws by the company or its management.
Currently, Alnylam Pharmaceuticals trades at $232.84, with a market capitalization of $31.16 billion. The stock’s 52-week range is between $197.81 and $495.55, showing significant price swings over the past year. The stock has lost about a quarter of its value since late July.
